Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.
GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.
Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.
The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 December 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results